Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the evidence actually says about switching between these two medicines
The biggest myth: 'just swap straight over on the next injection day'
Online forums are full of this advice and it is not quite right, but it is also not completely wrong. Because semaglutide (the active ingredient in Ozempic) and tirzepatide (the active ingredient in Mounjaro) both slow gastric emptying and suppress appetite, stacking their effects by switching carelessly can amplify nausea, vomiting and other gastrointestinal symptoms significantly. At the same time, the notion that you must wait weeks in a kind of pharmaceutical no-man's-land is equally unhelpful and not supported by any formal guideline.
The practical reality sits in between. Semaglutide has a half-life of roughly one week, meaning it takes around five weeks to leave the body almost entirely after a final dose. Most prescribers do not insist on waiting that long before starting tirzepatide, but they do factor in what dose of Ozempic you were taking, how your body tolerated it, and whether you had any ongoing side effects. A direct switch from a high maintenance dose of Ozempic to even the 2.5 mg starter pen of Mounjaro can still feel abrupt to some people, because GLP-1 receptor activation from the previous medicine may still be present. That is the nuance no algorithm captures.
The SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025 compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks and found tirzepatide produced greater average weight reduction, but it also started participants from scratch rather than mid-treatment switches. Real-world switches carry different considerations.
What a prescriber actually weighs up before the switch
Clinical judgment here comes down to a few practical questions. First, your current Ozempic dose: a weekly 0.5 mg injection behaves differently from a 2 mg dose in terms of residual receptor activity when you stop. Second, your reason for switching: if Ozempic stopped working, if you experienced intolerable side effects, or if your diabetes management changed, each scenario suggests a different gap and starting point on Mounjaro's titration ladder. Third, your weight-related health picture overall.
Most clinical guidance points toward starting Mounjaro at its 2.5 mg dose regardless of what you were taking before, because the first pen is a tolerability step, not a therapeutic target. Starting above that without a prescriber's specific direction would be inadvisable. NHS guidance on weight-management injections notes the importance of proper titration and wraparound care; you can read more at NHS England's page on weight-management injections.
For people asking about timing in the other direction, the gap between Mounjaro and Wegovy raises similar questions, and the same principle holds: individual assessment beats a fixed number of days.
Ozempic, Mounjaro, Wegovy: which is licensed for what in the UK
This matters because it shapes everything, including what a legitimate prescriber will and will not do. Ozempic (semaglutide) is licensed in the UK for type 2 diabetes. It is not licensed for weight loss. If you have been using it for weight management, that was an off-label use. Mounjaro (tirzepatide), as the NHS explains, is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, as well as for type 2 diabetes. Wegovy (semaglutide 2.4 mg weekly injection) carries the equivalent weight-loss licence.
So for anyone switching because weight management is the primary goal, Mounjaro and Wegovy are the two licensed options. You can compare the clinical picture of both medicines in the Wegovy vs Mounjaro breakdown on this site. Ozempic itself is not something a responsible prescriber would offer you specifically for weight loss when licensed alternatives exist.
| Factor | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| UK weight-loss licence | No — licensed for type 2 diabetes only | Yes (BMI ≥30, or ≥27 with comorbidity) |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Dosing | Weekly injection, 0.25–2 mg | Weekly injection, 2.5–15 mg |
| Head-to-head evidence | Comparator in SURMOUNT-5 at 2.4 mg (Wegovy dose) | Greater avg. weight loss vs semaglutide 2.4 mg in SURMOUNT-5 [NEJM, 2025] |
| Suitable switch starting dose | N/A (stopping point) | 2.5 mg, prescriber-directed |
What to do if you are mid-switch and wondering if it is working
A question our prescribers hear regularly: 'I switched a few weeks ago and feel like nothing is happening.' The early weeks on Mounjaro's 2.5 mg dose are not designed to produce dramatic results; they let your system adjust after stopping the previous medicine. Keep the new pen in the fridge door alongside whatever you keep up there, and use the same day and time each week to build the habit. If you are genuinely seeing no progress after reaching a higher maintenance dose, that is a different conversation, and the evidence around what realistic progress looks like after switching may be useful context.
People who have found Wegovy stopped working after a switch face a version of the same question from the other direction; the patterns are explored at why Wegovy may not work after switching from Mounjaro. And it is worth knowing from the outset that stopping either medicine carries its own trajectory: weight regain after stopping GLP-1 treatment is well-documented and part of the clinical picture a prescriber will discuss with you.
Which medicine suits you, and how to time a switch properly, is a clinical decision our prescribers make with you. If you are ready to talk it through, start your free consultation and a GPhC-registered prescriber will review your situation the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.